Abstract: A method for joining tissue comprising aligning and abutting edges of the tissue to be joined applying a biodegradable, biological solder or an analogue thereof, across the edges and exposing the solder to an energy source under conditions which provide transfer of energy from the source to the solder to cause the solder to bond to the tissue surface adjacent the edges to provide a weld holding the edges together.
Type:
Grant
Filed:
January 25, 2001
Date of Patent:
June 24, 2003
Assignees:
The Microsearch Foundation of Australia, Macquarie Research Ltd.
Inventors:
Earl Ronald Owen, Rodney Ian Trickett, Antonio Lauto, Judith Margaret Dawes, James Austin Piper
Abstract: An apparatus and a method for reading a gel electrophoresis pattern can read the gel electrophoresis pattern of a sample, such as a nucleic acid and a protein, with high sensitivity and without requiring the use of an expensive device structure such as a laser light source of unique type.
Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after the device has been inserted in a patient by administering to the device a pharmaceutically effective amount of a composition having:
(A) at least one taurinamide derivative, and
(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
Abstract: Disclosed are methods and compositions for treating proliferative disorders, such as cancers, blood vessel disorders, fibrotic disorders and acute or chronic rejection of transplanted organs, tissue or cells, using compounds of formula I or a tautomeric isomer thereof:
wherein R1 and R2 are as defined; or a pharmaceutically-acceptable salt or pro-drug thereof.
Abstract: Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine.
Abstract: Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds to achieve apoptotic ablation of internal organs or internal non-malignant cell populations are disclosed.
Abstract: Non-naturally occurring lytic peptides which contain a phenylalanine residue and one or more alanine, valine and lysine residues, and optionally contain chemically masked cysteine or serine residues possess an amphipathic structure which allows them to promote cell lysis in certain pathologic organisms, and particularly in prokaryotes. Peptides having a beta-pleated sheet secondary structure and lacking cysteine residues form one embodiment of these lytic peptides.
Abstract: A composition having antibacterial activity is disclosed. More particularly, a mixture of an oxazolidinone compound, sulbactam, and ampicillin active agents, demonstrating activity against resistant strains of bacteria is disclosed. Methods for using an oxazolidinone compound, sulbactam, and ampicillin to treat a bacterial infection are also described.
Abstract: The present invention generally relates to various methods for treating the laminitis syndrome in animals. These benefits are obtained by administering to the animals a composition containing an &agr;-adrenergic antagonist that does not substantially cross the blood brain barrier. In one embodiment, the &agr;-adrenergic antagonist is domperidone. The domperidone can be administered to the animal either orally, subcutaneously, or intramuscularly and can be used to treat animals suffering from symptoms of laminitis.
Abstract: A technique for realizing the wide application of penem compounds as pharmaceutical antibacterial compositions is disclosed. The composition contains a penem compound as an active ingredient characterized in that it contains an &agr;,&ohgr;-diamineacetate compound.
Abstract: A tooth coating composition contains shellac, solvent for the shellac, and mica titanium as the main constituents. The coating provided on teeth with such composition is excellent in its drying property, durability, color tone, and easiness of removal thereof. The content of the shellac in the whole composition is preferably from 6 to 12% by weight and the content of the mica titanium is preferably from 3.5 to 16% by weight.
Abstract: A pharmaceutical composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalents of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional analog. The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having an F0 of less than 3.0.
Type:
Grant
Filed:
February 10, 2000
Date of Patent:
February 18, 2003
Assignee:
N.V. Nutricia
Inventors:
Rudolf Leonardus Lodewijk Smeets, Robert Johan Joseph Hageman
Abstract: With an agent for preparing a medication for treating the symptoms of Parkinson's disease, one obtains more effective treatment of the symptoms of said disease compared to classical treatment by a combination of effective substances comprising a substance increasing dopamine concentration in the synaptic cleft of the neurons of the brain along with a local anesthetic of the anilide group.
Abstract: A magnesium citrate oral solution comprising citric acid in an amount greater than 10% weight/volume; magnesium hydroxide in an amount ranging from about 1.5-5% weight/volume; and water. Most preferably, the citric acid is present in an amount of about 10.9% weight/volume. Another embodiment of the present invention is a method of treating constipation in a patient in need thereof. The method of this embodiment comprises administering an effective amount of an oral composition that comprises citric acid in an amount greater than 10% weight/volume. Preferably, the composition of this embodiment comprises citric acid in an amount of 10.9% weight/volume.
Abstract: A method of activating the immune system of a subject comprises the chronic administration of low doses of an agent having cytokine activity, including natural and recombinant cytokines, fragments, analogues, fusion proteins, and derivatives thereof, that are pharmaceutically acceptable, and their mixtures with other biologically active agents and formulation ingredients. The agent is provided as a unit dosage form, in systemic and topical product form, as an implant, inhalant, transdermal delivery device, and ultrasound and electrotransport devices, as well as in the form of a kit for self-administration.
Abstract: This invention relates to substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and a topic disorders (for example, a topic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted benzo[1,2-b:5,4-b′]dipyran-4-amines which are CCR5 receptor antagonists. Furthermore, since CD8+T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therpeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.
Type:
Grant
Filed:
August 29, 2001
Date of Patent:
January 14, 2003
Assignee:
SmithKline Beecham Corporation
Inventors:
Frank E. Blaney, William E Bondinell, James A. Chan
Abstract: The present invention relates to a method of inhibiting or preventing infection and blood coagulation in or near a medical prosthetic device after said device has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising:
(A) at least one taurinamide derivative, and
(B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof, whereby there are no systemic anti-clotting and no systemic biocidal effects.
Abstract: The use of compounds of the milbemycin class as inhibitors of efflux pumps in microbes or other cells is described, along with pharmaceutical compositions incorporating a milbemycin. Also described is a method of screening for compounds which inhibit a CDR1, CDR2, BEN, or FLU1 efflux pump or a pump with components having a high level of protein level sequence similarity with the components of those efflux pumps.
Type:
Grant
Filed:
October 1, 1998
Date of Patent:
December 17, 2002
Assignee:
Essential Therapeutics, Inc.
Inventors:
Suzanne Chamberland, May Lee, Olga Lomovskaya
Abstract: A method for oxidizing an organic contaminant in an aqueous medium generates H2O2 in the aqueous medium through the use of a corona discharge procedure. A quantity of hydroxyl radicals is generated from the H2O2. An organic contaminant is oxidized in the aqueous medium by reacting the hydroxyl radicals with the organic contaminant, the oxidation being enhanced by methods for facilitating the generation of hydroxyl radicals.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 10, 2002
Assignee:
Florida State University
Inventors:
Bruce R. Locke, Amit K. Sharma, Wright C. Finney, Pedro G. Arce
Abstract: In a method for controlling sample introduction in microcolumn separation techniques, more particularly in capillary electrophoresis (CE), where a sample is injected as a sample plug into a sampling device which comprises at least a channel for the electrolyte buffer and a supply and drain channel for the sample. The supply and drain channels discharge into the electolyte channel at respective supply and drain ports. The distance between the supply port and the drain port geometrically defines a sample volume. The injection of the sample plug into the electrolyte channel is accomplished electrokinetically by applying an electric field across the supply and drain channels for a time at least long enough that the sample component having the lowest electrophoretic mobility is contained within the geometrically defined volume. The supply and drain channels each are inclined to the electrolyte channel. Means are provided for electrokinetically injecting the sample into the sample volume.
Type:
Grant
Filed:
January 31, 2001
Date of Patent:
December 10, 2002
Assignee:
Zeptosens AG
Inventors:
Andreas Manz, D. Jed Harrison, Carlo S. Effenhauser